Share-Value Dilution from the Exercise of Stock Acquisition Rights
First written in FY2022. 7 of 13 entries say "Materialised", first in FY2023-Q1. Latest entry: FY2026.
Lifedrink Company moved to the "Worse" side of this theme in 2022, 2 years after the typical company in this theme (2020).
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
32 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「As of 31 May 2026, the number was 1,595,900 shares, equivalent to 3.0% of the 52,329,809 issued shares.」
Unexercised stock acquisition rights increased from 56,400 shares, or 0.1%, in the previous fiscal year to 1,595,900 shares, or 3.0%. Potential dilution exposure from the Series 4 stock acquisition rights has expanded. - FY2026-H1WorsenedAnnual report
「Increase resulting from the exercise of stock acquisition rights." "Fourth Series of Stock Acquisition Rights pursuant to a resolution of the Board of Directors meeting held on 30 July 2025: Number of stock acquisition rights: 15,671 (1,567,100 common shares)」
During the current interim period, the number of issued shares increased by 16,800 through the exercise of stock acquisition rights, and dilution continued to occur. In addition, the Fourth Series of Stock Acquisition Rights covering 1,567,100 common shares was issued, increasing potential future dilution exposure. - FY2025MitigatedAnnual report
「As of 31 May 2025, the number was 56,400 shares, equivalent to 0.1% of the 52,280,264 issued shares.」
Unexercised stock acquisition rights were disclosed as 56,400 shares, or 0.1%, at the end of May 2025, compared with 20,100 shares, or 0.2%, in the previous fiscal year. Shares continued to be issued through exercise, but their proportion of total issued shares declined. - FY2025-H1MaterialisedAnnual report
「The increase resulted from the exercise of stock acquisition rights.」
The number of issued shares increased by a total of 3,000 through the exercise of stock acquisition rights from April to September 2024, and dilution of share value continued to occur. - FY2024MitigatedAnnual report
「As of 31 May 2024, the number was 20,100 shares, equivalent to 0.2% of the 13,058,295 issued shares.」
During the current fiscal year, 73,200 shares were issued through the exercise of stock acquisition rights and dilution continued. Meanwhile, unexercised stock acquisition rights declined from 92,400 shares, or 0.7%, in the previous fiscal year to 20,100 shares, or 0.2%. - FY2024-Q3MaterialisedAnnual report
「1 October 2023–31 December 2023 (Note 1): Increase resulting from the exercise of stock acquisition rights." "From 1 January 2024 to 31 January 2024, the number of issued shares increased by 9,300 through the exercise of stock acquisition rights.」
The number of issued shares increased by 13,500 through the exercise of stock acquisition rights during the third-quarter accounting period, and by a further 9,300 shares in January 2024, indicating that dilution continued to occur. - FY2024-Q2MaterialisedAnnual report
「From 1 October 2023 to 31 October 2023, the number of issued shares increased by 600 through the exercise of stock acquisition rights.」
During the second-quarter accounting period, the number of issued shares also increased by 3,600 through the exercise of stock acquisition rights, and increased by a further 600 shares in October 2023 before the filing date. The issuance of shares and resulting dilution through the exercise of stock acquisition rights continued. - FY2024-Q1MaterialisedAnnual report
「1 April 2023–30 June 2023 (Note 1): The issuance of new shares upon the exercise of stock acquisition rights increased total issued shares by 3,600, and increased stated capital and the capital surplus by ¥0 million each.」
The issuance of new shares through the exercise of stock acquisition rights continued during the first quarter, resulting in dilution of share value. - FY2023MitigatedAnnual report
「As of 31 May 2023, the number was 92,400 shares, equivalent to 0.7% of the 12,975,740 issued shares.」
Shares continued to be issued through the exercise of stock acquisition rights during the current fiscal year, resulting in dilution. Meanwhile, unexercised stock acquisition rights declined from the 4.0% equivalent disclosed for the previous fiscal year to 0.7%. - FY2023-Q3MaterialisedAnnual report
「The issuance of new shares upon the exercise of stock acquisition rights increased total issued shares by 72,000, and increased stated capital and the capital surplus by ¥6 million each.」
The number of issued shares increased by 72,000 through the exercise of stock acquisition rights during the third-quarter accounting period. It also increased by 2,100 shares during January 2023, indicating that dilution continued to occur. - FY2023-Q2MaterialisedAnnual report
「The issuance of new shares upon the exercise of stock acquisition rights increased total issued shares by 254,100, and increased stated capital and the capital surplus by ¥1 million each.」
The number of issued shares increased through the exercise of stock acquisition rights during the second quarter. It also increased by 22,500 shares during October 2022. - FY2023-Q1MaterialisedAnnual report
「From 1 July 2022 to 31 July 2022, the number of issued shares increased by 212,100 shares through the exercise of stock acquisition rights.」
The number of issued shares increased by 212,100 through the exercise of stock acquisition rights, indicating that the dilution of share value previously identified as a risk had actually occurred. - FY2022First statedAnnual report
「As of the end of the month preceding the filing date of this document, 31 May 2022, the number was 510,900 shares, equivalent to 4.0% of the 12,550,500 issued shares. If these stock acquisition rights are exercised, new shares in the company will be issued, potentially diluting the value of shares held by existing shareholders.」
Stock acquisition rights issued to directors and employees, covering 510,900 shares, represent 4.0% of total issued shares, and dilution upon exercise is identified as a risk.